CJC-1295 + Ipamorelin FAQ: Your Questions Answered
The questions below are the ones that come up specifically about CJC-1295 + Ipamorelin, rather than general peptide questions that apply to everything.
In plain English
Usual questions: why the two are combined, what makes Ipamorelin selective, how to read a blend report, and the difference between CJC-1295 with and without DAC.
What CJC-1295 + Ipamorelin actually is
This is a blend of two separate molecules rather than one. CJC-1295 is a shortened version of the natural growth hormone signal with four amino acids swapped for resistance. Ipamorelin works through a completely different receptor. They are paired because they reach the same result by two independent routes.
Supplied for laboratory research use only — not for human or animal use.
Third-party tested by HPLC and LC-MS, ≥99% purity, with a Certificate of Analysis on every order. Ships across Canada.
Technical detail below
CJC-1295 + Ipamorelin — common questions
Why are CJC-1295 and Ipamorelin combined?
They act on different receptors. CJC-1295 is a GHRH-receptor agonist and Ipamorelin a ghrelin-receptor agonist, so their signals converge on GH release through independent pathways. Research designs pair them for that complementarity rather than because either is deficient alone.
What makes Ipamorelin "selective"?
Earlier GH secretagogues, GHRP-6 among them, also stimulated cortisol and prolactin release. Ipamorelin was developed to retain GH-releasing activity while largely avoiding those effects, and that selectivity is the reason it superseded the earlier compounds in much of the research literature.
How should I read a COA for a blended product?
Look for two resolved peaks and two confirmed masses, with a stated ratio between components. A single aggregate purity figure tells you the vial contains 99% peptide but says nothing about whether the two peptides are present in the intended proportion — which is the specific thing that can go wrong with a blend.
What is the difference between CJC-1295 with and without DAC?
DAC (Drug Affinity Complex) is a linker that binds serum albumin, extending half-life from minutes to days. The version without DAC — often called Modified GRF (1-29) — retains the degradation-resistant substitutions but not the albumin-binding extension. Research literature is not always explicit about which was used, which is a common source of confusion when comparing studies.
What CJC-1295 + Ipamorelin is studied for
GHRH-receptor and ghrelin-receptor agonism act through different mechanisms, which is the rationale for pairing them.
Developed specifically for GH release with minimal cortisol and prolactin effects — its defining pharmacological feature.
Studied for effects on the pattern of GH secretion rather than continuous elevation.
A common endpoint in the preclinical literature for GH-axis compounds.
Summarizes published preclinical literature. Provided for research reference only; not a claim of efficacy or a description of human use.
More CJC-1295 + Ipamorelin reference
Lyophilized and reconstituted storage conditions, plus the practical working window.
Diluent selection, dissolution behaviour, and the calculator preset for this compound.
Which solvents work, why, and what abnormal dissolution behaviour indicates.
The specific chemical routes by which this molecule breaks down, and how to limit each.
Which assays are informative for this molecule, and what to actually check on its COA.
Compound-specific bench practices, and the errors most often made with this molecule.
What to inspect on arrival, and which conditions actually warrant rejecting a vial.
FAQ reference for other compounds
CJC-1295 + Ipamorelin is supplied strictly as a research chemical for in-vitro laboratory and research use only. It is not intended for human or animal consumption, diagnostic, or therapeutic use. This page is educational laboratory-handling reference information — not medical advice, not usage guidance, and not a protocol.